LEDDEGIGT – - Sundhedsstyrelsen

Litteratur
1 Jonsson D, Husberg M.
Socioeconomic costs of
rheumatic diseases.
Implications for technology
assessment. Int J
Technol Assess Health
Care 2000; 16(4):1193-
1200.
2 Lindegaard HM.
Early Rheumatoid
Arthritis (PhD). Odense:
Syddansk Universitet,
2002.
3 Jobanputra P, Barton P,
Bryan S, Fry-Smith A,
Burmester GR.
The clinical effectiveness
and cost-effectiveness
of new drug treatments
for rheumatoid
arthritis: etanercept
and infliximab. Health
Technol Assess 2002;
6(21).
4 Choi HK, Seeger JD,
Kuntz KM.
A cost-effectiveness
analysis of treatment
options for patients
with methotrexate-resistant
rheumatoid
arthritis. Arthritis
Rheum 2000;
43(10):2316-2327.
5 Choi HK, Seeger JD,
Kuntz KM.
A cost effectiveness
analysis of treatment
options for methotrexatenaive
rheumatoid
arthritis. J Rheumatol
2002; 29(6):1156-1165.
6 Yazdani C, McLaughlin
T, Cummins G, Doyle J.
Comparison of rheumatoid
arthritis care costs
in patients starting
therapy with leflunomide
versus etanercept.
Am J Manag Care 2001;
7(13 Suppl):S419-S426.
7 Ollendorf DA, Peterson
AN, Doyle J, Huse DM.
Impact of leflunomide
versus biologic agents
on the costs of care for
rheumatoid arthritis in
a managed care population.
Am J Manag Care
2002; 8(7 Suppl):S203-
S213.
8 Nuijten MJ, Engelfriet P,
Duijn K, Bruijn G, Wierz
D, Koopmanschap M.
A cost-cost study comparing
etanercept with
infliximab in rheumatoid
arthritis. Pharmacoeconomics
2001;
19(10):1051-1064.
9 Yazici Y, Erkan D, Leff L,
Kulman I, Schwartzman
S, Harrison MJ.
Infliximab in the treatment
of rheumatoid
arthritis: 18 months’ experience
of referral patterns,
response to treatment
and adverse
events in ’real world’
practice setting. Ann
Rheum Dis 2002;
61(Suppl. 1):380.
10 Crnkic M, Petersson IF,
Saxne T, Geborek P.
Tolerability using survival
on drug as evaluation
tool. Experience of
etanercept and infliximab
in rheumatoid
arthritis (RA). Ann
Rheum Dis 2002;
61(Suppl. 1):177.
11 Yazici Y, Erkan D,
Kulman I, Harrison MJ,
Schwartzman S.
Infliximab for the treatment
of rheumatoid
arthritis: do outcomes
at 1 year in the “real
world” match clinical
trials’ data? Ann Rheum
Dis 2002; 61(Suppl.
1):196.
12 Cientifico C.
Spanish experience
with a registry of adverse
events in biological
therapy. Ann Rheum
Dis 2002; 61(Suppl.
1):388.
13 Ridley D, Moreta E.
Effective management
of rheumatoid arthritis
through dose titration
of anti-TNF agents. Ann
Rheum Dis 2002;
61(Suppl. 1):184.
14 Van Vollenhoven RF,
Gullström E, Brannemark
S, Klareskog L.
Dose escalation of infliximab
in clinical practice:
data from the
Stockholm TNF-alpha
registry (Sture). Ann
Rheum Dis 2002;
61(Suppl. 1):177.
15 Bathon JM, Martin RW,
Fleischmann RM, Tesser
JR, Schiff MH, Keystone
EC et al.
A comparison of etanercept
and methotrexate
in patients with early
rheumatoid arthritis.
N Engl J Med 2000;
343(22):1586-1593.
16 Feltelius NJV, Lindblad
S, Fored M, Jacobsson
LTH, Lysholm J,
Klintberg K et al.
A national drug monitoring
system - TNF
blocker treatment in
patients with rheumatoid
arthritis. Ann
Rheum Dis 2002;
61(Suppl. 1):173.
17 Shergy W, Harshbarger
JL, Lee W, McCain J,
Schimizzi GF, Snow DH
et al.
Commercial experience
with rheumatoid arthritis
(RA) patients switching
from etanercept to
infliximab. Ann Rheum
Dis 2002; 61(Suppl.
1):178.
18 Kavanaugh A,
Heudebert G, Cush J,
Jain R.
Cost evaluation of novel
therapeutics in
rheumatoid arthritis
(CENTRA): a decision
analysis model. Semin
Arthritis Rheum 1996;
25(5):297-307.
19 Geborek P, Eberhardt K,
Saxne T.
Etanercept and infliximab
treatment reduces
hospital care in arthritis
patients. Ann Rheum
Dis 2002; 61(Suppl.
1):192.
20 Eberhardt K, Saxne T,
Geborek P.
Etenercept and infliximab
treatment improves
health status in
arthritis patients. Ann
Rheum Dis 2002;
61(Suppl. 1):192.
21 Van Vollenhoven R.F.,
Harju A, Bratt J,
Brannemark S, Van
Vollenhoven A,
Lindblad S et al.
Treatment with infliximab
or etanercept results
in significant increases
in work force
participation: data from
the Stockholm TNF-alpha
antagonist registry
(Sture). Ann Rheum Dis
2002; 61(Suppl. 1):182.
22 Klareskog L, Wajdula J,
Pedersen R.
A long-term, open-label
trial of the safety and
efficacy of etanercept
(25 mg twice weekly) in
patients with rheumatoid
arthritis (interim
analysis). Ann Rheum
Dis 2002; 61(Suppl.
1):175.
23 Kremer JM, Weinblatt
ME, Fleischmann RM,
Bankhurst AD, Burge DJ.
Etanercept (En-brel(r))
in addition to methotrexate
in rheumatoid
arthritis: long-term observations.
Ann Rheum
Dis 2002; 61(Suppl.
1):181.
24 Durez P, Devogelaer JP,
Van den Bosch F,
Kruithof E, Peretz A,
Verbruggen L et al.
Infliximab and
methotrexate in the
treatment of rheumatoid
arthritis: clinical
results in a Belgian observational
cohort. Ann
Rheum Dis 2002;
61(Suppl. 1):379.
136 LEDDEGIGT – medicinsk teknologivurdering af diagnostik og behandling
LEDDEGIGT – medicinsk teknologivurdering af diagnostik og behandling 137